Table 1.

Current pharmacological strategies for treatment of cognitive deficits in tauopathies.

Year Approved	Drug	Brand Name	Disease Stage	Mechanism of Action	Disease Modifying	Delay Disease Progression
1996	Donepezil	Aricept	All stages	Cholinesterase inhibitor	No	No
2000	Rivastigmine	Exelon	All stages	Cholinesterase inhibitor	No	No
2001	Galantamine	Razadyne	Mild to moderate	Cholinesterase inhibitor	No	No
2003	Memantine	Namenda	Moderate to Severe	NMDA receptor antagonist	No	No
2014	Donepezil+ Memantine	NAMZARIC	Moderate to Severe	Cholinesterase inhibitor + NMDA receptor antagonist	No	No